Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo- and Active-controlled Parallel-group Multi-center Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo- and Active-controlled Parallel-group Multi-center Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs YY-001 (Primary) ; Botulinum Toxin A
  • Indications Glabellar lines
  • Focus Registrational; Therapeutic Use
  • Sponsors Chongqing Claruvis Pharmaceutical

Most Recent Events

  • 28 Apr 2026 According to Chongqing Claruvis Pharmaceutical media release, Primary endpoint (At the 1st week, 8th week, and 12th week after treatment, the composite response rate on both the investigators assessment and the participants self- assessment concurrently of GL severity at maximal frown.) has been met.
  • 28 Apr 2026 According to Chongqing Claruvis Pharmaceutical media release, Primary endpoint (The 4th week after treatment, the composite response rate on both the investigators assessment and the participants self-assessment concurrently of GL severity at maximal frown.) has been met.
  • 28 Apr 2026 According to Chongqing Claruvis Pharmaceutical media release, company announced that the Chinas National Medical Products Administration (NMPA) has approved its Retoxin (recombinant botulinum toxin type A, project code YY001) for the temporary improvement of moderate-to-severe glabellar lines in adult patients.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top